Go to main content

Press Releases

Explore the archived press releases about AOP Health, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via aop-health@aoporphan.com 

AOP Orphan Statement on SARS-CoV-2 and COVID-19

17. 3. 2020

AOP Orphan Pharmaceuticals AG, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia

13. 5. 2019

AOP Orphan Pharmaceuticals AG and Amomed Pharma GmbH announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria.

19. 6. 2017

AOP Orphan Pharmaceuticals AG announces European “approvable” opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol)

11. 7. 2016

AOP Orphan to be commercialization partner for Canadian pharmaceutical specialist Cardiome

10. 12. 2014

AOP Orphan to market the innovative antiarrhythmic drug BRINAVESS® exclusively in Central Europe

25. 8. 2014